Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease - Effect of L-Dopa

Journal of Neural Transmission

Volumn 103, Issue 5, 1996, Pages 591-602

  Strittmatter, M ^a   Hamann, G F ^a   Strubel, D ^c   Cramer, H ^b   Schimrigk, K ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Pavillon Schutzenberger   (France)

Author keywords

Cerebrospinal fluid; Dementia; Monoamines; Parkinson's disease; Somatostatin like immunoreactivity

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANTIPARKINSON AGENT; HOMOVANILLIC ACID; LEVODOPA; MONOAMINE; SOMATOSTATIN;

AGED; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METABOLITE; MOLECULAR WEIGHT; NERVE CELL DEGENERATION; NERVE CELL NETWORK; NEUROCHEMISTRY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PROCESSING; RADIOIMMUNOASSAY;

AGED; AGED, 80 AND OVER; AGING; BIOGENIC MONOAMINES; DEMENTIA; FEMALE; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; MOLECULAR WEIGHT; PARKINSON DISEASE; PEPTIDES; SOMATOSTATIN;

EID: 0029842332     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01273156     Document Type: Article

References (50)

1. Asanuma M, Ogawa N, Sora YH, Pongdhana K, Haba K, Mori A (1990) Alterations of somatostatin and its modulation by levodopa in MPTP-treated mouse brain. J Neurol Sci 100: 155-160
2. Bartfai T (1985) Presynaptic aspects of the coexistence of classical neurotransmitters and peptides. Trends Pharmacol Sci 6: 331-334
3. Beal MF, Martin J (1984) The effect of somatostatin on striatal catecholamines. Neurosci Lett 44: 271-276
4. Beal MF, Mazurek MF, Martin JB (1986) Somatostatin immunoreactivity is reduced in Parkinson's disease dementia with Alzheimer's changes. Brain Res 397: 386-388
5. Beal MF, Mazurek MF, Mc Black PL, Martin JB (1985) Human cerebrospinal fluid somatostatin in neurologic disease. J Neurol Sci 71: 91-104
6. Campell MJ, Lewis DA, Benoit R, Morrison JH (1987) Regional heterogeneity in the distribution of somatostatin-28 and somatostatin 28 (1-12) immunoreactive profiles in the monkey neocortex. J Neurosci 7(4): 1133-1144
7. Chesselet MF, Reisine TP (1983) Somatostatin regulates dopamine release in rat striatal slices and cat caudate nuclei. Neuroscience 3: 332-336
8. Cuadra G, Summers K, Giacobini E (1994) Cholinesterase inhibitor effects on neurotransmitter in rat cortex in vivo. J Pharmacol Exp Ther 270: 277-284
9. Cutler NR, Haxby JV, Narang PK, May C, Burg C, Reines SA (1984) Evaluation of an analogue of somatostatin (L363, 586) in Alzheimer's disease. N Engl J Med 312: 725
10. Davies P, Katzman R, Terry RD (1980) Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer's disease and Alzheimer senile dementia. Nature 288: 279-280
11. Davies P, Terry RD (1981) Cortical somatostatin-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer's type. Neurobiol Aging 2: 9-14
12. Dournaud P, Cervera-Pierot P, Hirsch E, Javoy-Agid F, Kordon C, Agid Y, Epelbaum J (1994) Somatostatin messenger RNA-containing neurons in Alzheimer's disease: an in situ hybridization study in hippocampus, parahippocampal cortex and frontal cortex. Neuroscience 61: 755-764
13. Dupont D, Hansen AP, Juul-Jensen P (1978) Somatostatin in the treatment of patients with extrapyramidal disorders and patients with EEG abnormalities. Acta Neurol Scand 57: 488-493
14. Dupont E, Christensen SE, Hansen AP, Olivarius BF, Orskov H (1982) Low cerebrospinal fluid in Parkinson's disease. Neurology 32: 312-314
15. Edvinsson L, Minthon L, Ekman R, Gustafson L (1993) Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration. Dementia 4: 167-171
16. Epelbaum J, Ruberg M, Moyse E, Javoy-Agid F, Dubois B, Agid Y (1983) Somatostatin and dementia in Parkinson's disease. Brain Res 278: 376-379
17. Folstein MF, Folstein SE, Mc Hugh PR (1975) Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198
18. Finali G, Piccirilli M, Piccinin GL (1994) Neuropsychological correlates of L-deprenyl therapy in idiopathic parkinsonism. Prog Neuropsychopharmacol Biol Psychiatry 18: 115-128
19. Fuxe K, Agnati LF, Benfenati F (1983) Evidence for the existence of receptor - receptor interactions in the central nervous system: studies on the regulation of monoamine receptors in neuropeptides. J Neural Transm 18 [Suppl]: 165-179
20. Gaykema RP, Gaal G, Traber J, Hersh LB, Luiten PG (1991) The basal forebrain cholinergic system: efferent and afferent connectivity and long-term effects of lesions. Acta Psychiatr Scand 366: 14-26
21. Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A, Eckernas SA, Nordberg A, Oreland L, Svennerholm L, Wiberg A, Winblad B (1983) Biochemical changes in dementia disorders of Alzheimer type. Neurobiol Aging 4: 261-271
22. Griffiths PD, Perry RA, Crossman AR (1994) A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease. Neurosci Lett 169: 68-72
23. Ham J, Duberley R, Rickards C, Scanlon MF (1993) Differential responses of rat cerebral somatostatinergic and cholinergic cells to glutamate agonists. Mol Chem Neuropathol 19: 107-120
24. Hartikainen P, Reinikainen KJ, Soininen H, Sirvio J, Soikkeli R, Riekkinen PJ (1992) Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. J Neural Transm [PD Sect] 4: 53-68
25. Herregodts P, Bruyland M, De Keyser J, Solheid C, Michotte Y, Ebinger G (1989) Monoaminergic neurotransmitter in Alzheimer disease. J Neurol Sci 92: 101-116
26. Hoehn M, Yahr MD (1967) Parkinsonism. Onset, progression and mortality. Neurology 17: 427-444
27. Jellinger K (1986) Overview of morphological changes in PD. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 457-461
28. Jellinger K (1991) Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14: 153-197
29. Jolkkonen J, Soininen H, Halonen T (1986) Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementia. J Neurol Neurosurg Psychiatry 49: 1374-1377
30. Kawakatsu S, Morinobu S, Shinohara M, Totsuka S, Kobashi K (1990) Acetylcholine activities and monoamine metabolites in the cerebrospinal fluid of patients with Alzheimer's disease. Biol Psychiatry 28: 387-400
31. Konings CH, Kuiper MA, Mulder C, Calliauer J, Wolters EC (1995) CSF acetylcholinesterase in Parkinson's disease: decreased enzyme activity and immunreactivity in demented patients. Clin Chem Acta 235: 101-105
32. Leake A, Ferrier IN (1993) Alterations in aging and disease. Pathophysiology and potential for clinical intervention. Drugs Aging 3: 408-427
33. Leake A, Perry EK, Perry RH, Jabeen S, Fairbairn AF, Mc Keith IG, Ferrier IN (1991) Neocortical concentrations of neuropeptides in senile dementia of the Alzheimer type and Lewy body type: comparison with Parkinson's disease and severity correlations. Biol Psychiatry 29: 357-364
34. Mahler ME, Cummings JL (1990) Alzheimer disease and the dementia of Parkinson's disease: comparative investigations. Alzheimer Dis Assoc Disord 4: 133-149
35. Martignoni E, Bono G, Blandini F, Sinforiani E, Merzo P, Nappi G (1991) Monoamines and related metabolic levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl. J Neural Transm [PD Sect] 15-25
36. Minthon L, Edvinsson L, Ekman R, Gustafson L (1990) Neuropeptide levels in Alzheimer's disease and dementia with frontotemporal degeneration. J Neural Transm [Suppl] 30: 57-67
37. Morrison JH, Rogers J, Scherr S, Benoit R, Bloom FE (1985) Somatostatin immunoreactivity in neuritic plaques of Alzheimer patients. Nature 314: 90-92
38. Nemeroff CB, Kizer JS, Reynolds GP, Bisette GP (1989) Neuropeptides in Alzheimer's disease: a post-mortem study. Reg Pept 25: 123-130
39. Procter AW, Francis PT, Stratmann GC, Bowen DM (1992) Serotonergic pathology is not widespread in Alzheimer patients without aggressive symptoms. Neurochem Res 17: 917-922
40. Quinn NP, Rossor N, Marsden CD (1986) Dementia and Parkinson's disease - pathological and neurochemical considerations. Br Med Bull 42(1): 86-90
41. Reisberg B, Ferris SH, De Leon MJ, Crook T (1982) The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 139: 1136-1139
42. Rissler K, Cramer H, Schaudt D, Strubel D, Gattaz WF (1986) Molecular size distribution of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with degenerative brain disease. Neurosci Res 3: 213-225
43. Strittmatter M, Cramer H (1992) Parkinson's disease and dementia: clinical and neurochemical correlations. Neuroreport 3: 413-416
44. Unsicker K (1993) The trophic cocktail made by adrenal chromaffin cells. Exp Neurol 123: 167-173
45. Vescei L, Widerloev E (1990) Preclinical and clinical studies with somatostatin related to the central nervous system. Prog Neuropsychopharmacol Biol Psychiatry 14: 573-602
46. Vescei L, Widerloev E, Alling C, Zsigo J, Pavo I, Penke B (1990) Somatostatin-28 (15-28), but not somatostatin-28 (1-12), affects central monoaminergic neurotransmission in rats. Neuropeptides 16(4): 181-186
47. Weber SJ, Louis RB, Trombley L, Bisette G, Davies P, Davies TP (1992) Metabolic half-life of somatostatin and peptidase activities are altered in Alzheimer's disease. J Gerontol 47(1): 18-25
48. Whitford CA, Candy JM, Edwardson JA, Perry RH (1988) Cortical somatostatinergic system not affected in Alzheimer's and Parkinson's disease. J Neurol Sci 86: 13-18
49. Yoshimura M (1988) Pathological basis for dementia in elderly patients with idiopathic Parkinson's disease. Eur Neurol 28: 29-35
50. Zorilla R, Simard J, Rheaume E, Labrie F, Pelletier G (1990) Multihormonal control of pre-pro-somatostatin mRNA levels in the periventricular nucleus of the male and female rat hypothalamus. Neuroendocrinology 52: 527-536